0
0
11/11/22 at 5:49pm
Organization
Ajmc.com
35 words
0
Comments
Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.
You are the first to view
https://www.ajmc.com/view/penpulimab-plus-anlotinib-evaluated-for-previously-treated-urothelial-cancers
Create an account
or login to join the discussion